A133V

Category 3/4 — Most DruggableUncertain significanceCytoplasmic · predictedSource card

Alanine → Valine at position 133 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type A133 — hydrogen bond to R138

Fullscreen ↗

DynaMut2 mutant · A133V

Mutant V133 — van der waals contact to R138 lost

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost7 gained12 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	—	T104	Gained
Hydrogen bond	W129	W129	Preserved
Hydrogen bond	Q136	Q136	Preserved
Hydrogen bond	R138	R138	Preserved
Polar contact	—	P100	Gained
Polar contact	—	T104	Gained
Polar contact	W129	W129	Preserved
Polar contact	L130	L130	Preserved
Polar contact	V131	V131	Preserved
Polar contact	Q136	Q136	Preserved
Polar contact	R138	R138	Preserved
Van der Waals	—	L130	Gained
Van der Waals	—	K135	Gained
Van der Waals	Q136	—	Lost
Van der Waals	R138	R138	Preserved
Hydrophobic	—	P100	Gained
Hydrophobic	Q103	Q103	Preserved
Hydrophobic	—	L130	Gained
Hydrophobic	R138	R138	Preserved
Hydrophobic	A141	A141	Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-0.51kcal/mol

Destabilising — mild

AlphaMissense

0.941

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, single submitter

Associated conditions—

Population frequency (gnomAD v4)Ultra-rare · AF 0.00014%

cDNA changec.398C>T

ClinVar accessionVCV003633039

Last evaluated2024/01/21 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — A133V Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Alanine → Valine at position 133. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.941, DynaMut2 ΔΔG -0.51 kcal/mol (destabilising).

Identity

Field	Value
Variant	A133V (p.Alanine133Valine)
DNA change	c.398C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV003633039
Amino acid change	Alanine (A) → Valine (V)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 133	92.00 — well-folded
Domain	N-terminal cytoplasmic (intrinsically disordered)
Position context	N-terminal cytoplasmic (intrinsically disordered)
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 133 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is small/hydrophobic (alanine — methyl sidechain); the mutant is small hydrophobic (valine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.9406
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-0.51 (Destabilising)
Job ID	178092143075
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092143075

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, single submitter
Last evaluated	2024/01/21 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	A133V is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.51 < 2 kcal/mol (fold intact) + AlphaMissense 0.941 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.51 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.941. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
A133V_molstar_viewer.html — interactive 3D viewer (auto-highlights position 133 with ball-and-stick + neighbors within 5Å)
A133V_variant_card.md — this card (source of truth)
A133V_variant_card.html — styled printable card
A133V_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
A133V_wildtype_interactions.pse / A133V_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A133V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A133V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.